WINTON GROUP Ltd Invests $1.28 Million in Royalty Pharma PLC $RPRX

Key Points

• WINTON GROUP Ltd initiated a $1.28 million position in Royalty Pharma during the second quarter by purchasing 22,800 shares. Institutional investors currently own 54.35% of the company.
• Royalty Pharma exceeded quarterly earnings expectations, reporting $1.32 in EPS versus the $1.27 consensus estimate, though revenue of $674.14 million fell short of the $758.93 million estimate.
• Analysts maintain a favorable outlook, with a consensus “Buy” rating and a $61.29 price target. The company also pays a $0.235 quarterly dividend, equivalent to a 1.6% yield.

WINTON GROUP Ltd bought a new position in Royalty Pharma PLC (NASDAQ:RPRX - Free Report) during the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund bought 22,800 shares of the biopharmaceutical company's stock, valued at approximately $1,278,000.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. LM Advisors LLC purchased a new position in Royalty Pharma during the 4th quarter valued at $26,000. Lloyd Advisory Services LLC. bought a new stake in shares of Royalty Pharma during the 4th quarter valued at about $30,000. Blue Trust Inc. increased its position in shares of Royalty Pharma by 173.4% during the first quarter. Blue Trust Inc. now owns 689 shares of the biopharmaceutical company's stock valued at $33,000 after buying an additional 437 shares during the period. CIBC Private Wealth Group LLC raised its stake in Royalty Pharma by 66.4% in the fourth quarter. CIBC Private Wealth Group LLC now owns 1,118 shares of the biopharmaceutical company's stock worth $43,000 after buying an additional 446 shares in the last quarter. Finally, Larson Financial Group LLC raised its stake in Royalty Pharma by 31.9% in the third quarter. Larson Financial Group LLC now owns 1,264 shares of the biopharmaceutical company's stock worth $45,000 after buying an additional 306 shares in the last quarter. 54.35% of the stock is currently owned by institutional investors.

Royalty Pharma Stock Performance

Shares of NASDAQ RPRX opened at $58.61 on Monday. The firm's 50 day moving average price is $59.33 and its 200-day moving average price is $53.67. Royalty Pharma PLC has a 52-week low of $34.63 and a 52-week high of $64.38. The company has a debt-to-equity ratio of 0.88, a quick ratio of 2.80 and a current ratio of 2.80. The company has a market cap of $33.70 billion, a PE ratio of 40.42, a P/E/G ratio of 1.38 and a beta of 0.44.

Royalty Pharma (NASDAQ:RPRX - Get Free Report) last announced its quarterly earnings results on Wednesday, August 5th. The biopharmaceutical company reported $1.32 earnings per share for the quarter, beating the consensus estimate of $1.27 by $0.05. Royalty Pharma had a net margin of 32.14% and a return on equity of 30.01%. The company had revenue of $674.14 million during the quarter, compared to the consensus estimate of $758.93 million. On average, equities research analysts expect that Royalty Pharma PLC will post 5.32 EPS for the current fiscal year.

Royalty Pharma Dividend Announcement

The firm also recently announced a quarterly dividend, which was paid on Thursday, September 10th. Shareholders of record on Friday, August 14th were issued a $0.235 dividend. The ex-dividend date of this dividend was Friday, August 14th. This represents a $0.94 dividend on an annualized basis and a dividend yield of 1.6%. Royalty Pharma's dividend payout ratio (DPR) is presently 64.83%.

Analyst Ratings Changes

RPRX has been the topic of a number of research analyst reports. The Goldman Sachs Group reiterated a "buy" rating and set a $66.00 target price on shares of Royalty Pharma in a report on Thursday, August 6th. Morgan Stanley restated an "overweight" rating and issued a $65.00 target price on shares of Royalty Pharma in a research note on Thursday, August 6th. Wall Street Zen upgraded Royalty Pharma from a "buy" rating to a "strong-buy" rating in a research report on Saturday. Weiss Ratings reaffirmed a "buy (b-)" rating on shares of Royalty Pharma in a research note on Wednesday, August 12th. Finally, JPMorgan Chase & Co. increased their price objective on Royalty Pharma from $58.00 to $62.00 and gave the stock an "overweight" rating in a report on Friday, August 7th. Eight research analysts have rated the stock with a Buy rating, According to data from MarketBeat, the stock presently has a consensus rating of "Buy" and a consensus price target of $61.29.

Insiders Place Their Bets

In other news, EVP Christopher Hite sold 100,000 shares of the business's stock in a transaction on Tuesday, August 18th. The stock was sold at an average price of $59.97, for a total value of $5,997,000.00. Following the completion of the transaction, the executive vice president owned 370,401 shares in the company, valued at $22,212,947.97. The trade was a 21.26% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Marshall Urist sold 9,099 shares of the company's stock in a transaction on Wednesday, July 1st. The shares were sold at an average price of $55.88, for a total value of $508,452.12. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last three months, insiders sold 398,197 shares of company stock valued at $22,513,280. Corporate insiders own 18.84% of the company's stock.

Royalty Pharma Profile

Royalty Pharma plc is a biopharmaceutical royalty company that provides funding to life sciences companies in exchange for rights to receive future royalty payments from commercialized or late-stage therapies. Rather than developing and marketing medicines itself, the company invests in pharmaceutical and biotechnology innovations and seeks to generate income from the resulting royalty streams.

Its portfolio is linked to a range of therapies across areas including oncology, immunology, neuroscience, rare diseases and other specialty markets.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.